Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$18.4 million.

  • BioXcel Therapeutics' Consolidated Net Income rose 55.23% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.2 million, marking a year-over-year increase of 2477.86%. This contributed to the annual value of -$79.8 million for FY2024, which is 5554.56% up from last year.
  • BioXcel Therapeutics' Consolidated Net Income amounted to -$18.4 million in Q3 2025, which was up 55.23% from -$19.8 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Consolidated Net Income peaked at -$13.8 million during Q1 2025, and registered a low of -$54.3 million during Q4 2022.
  • Its 4-year average for Consolidated Net Income is -$31.8 million, with a median of -$26.8 million in 2024.
  • Per our database at Business Quant, BioXcel Therapeutics' Consolidated Net Income tumbled by 6697.38% in 2023 and then soared by 6341.79% in 2024.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Consolidated Net Income stood at -$54.3 million in 2022, then surged by 58.84% to -$22.4 million in 2023, then skyrocketed by 36.7% to -$14.2 million in 2024, then decreased by 29.72% to -$18.4 million in 2025.
  • Its Consolidated Net Income was -$18.4 million in Q3 2025, compared to -$19.8 million in Q2 2025 and -$13.8 million in Q1 2025.